Soojin Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Soojin Hwang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Beom Hee Lee
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
6 shared publications - Han-Wook Yoo
Department of Pediatrics, CHA Bundang Medical Center, CHA University, Seongnam, Korea
6 shared publications - Ji-Hee Yoon
Asan Medical Center, University of Ulsan College of Medicine
6 shared publications - Jin-Ho Choi
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
5 shared publications - Gu-Hwan Kim
Medical Genetics Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4 shared publications - Ja Hye Kim
Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, South Korea
4 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
Long-Term Maintenance Therapy with Carglumic Acid in Children with Propionic or Methylmalonic Acidemia: Impact on Metabolic Stability and Neurodevelopment
Background: Patients with an organic acidemia, such as propionic acidemia (PA) or methylmalonic acidemia (MMA), often experience metabolic decompensation episodes characterized by metabolic acidosis and hyperammonemia. The long-term effects of carglumic acid (N-carbamylglutamate) therapy in children with PA and MMA were evaluated using comprehensive assessments including neurodevelopment, growth, and metabolic profiles.Methods: Three pediatric patients diagnosed with organic acidemias (2 PA, 1 MMA) and recurrent metabolic decompensation episodes were administered carglumic acid (50 mg/kg/day). The primary outcomes were total hospitalization days and the annual admission rate due to metabolic decompensation. Secondary outcomes including biochemical tests and adverse events were also evaluated.Results: The patients received carglumic acid for a median duration of 3.2 years (range, 2.8-3.4). Over this period, the median annual hospitalization days decreased from 35 (range, 15–259) to 0 (range, 0–39), and the median annual admission rate from 2 (range, 0.8–4.0) to 0 (range, 0–4). Peak ammonia levels decreased from a median of 411 μmol/L (range, 232–615) to 77 μmol/L (range, 74–80). Plasma levels of isoleucine, valine, and C3-acylcarnitine remained stable. No further deterioration in growth or neurodevelopment was observed. Notably, the MMA patient who received this treatment from 2 months of age achieved age-appropriate developmental milestones after 2.5 years. All three children showed good treatment adherence, and no drug-related adverse events were reported. Additionally, we identified a novel PCCB missense variant, c.520G>C (p.Ala174Pro), in one patient with PA. This variant was detected in trans with a previously reported canonical splice-site variant, c.966+1G>T, and was classified as likely pathogenic according to ACMG/AMP criteria.Conclusion: Early and sustained maintenance therapy with carglumic acid in children with organic acidemias may effectively reduce hyperammonemic decompensation, stabilize metabolic control, and support favorable neurodevelopmental outcomes.
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLong-Term Maintenance Therapy with Carglumic Acid in Children with Propionic or Methylmalonic Acidemia: Impact on Metabolic Stability and Neurodevelopment
Background: Patients with an organic acidemia, such as propionic acidemia (PA) or methylmalonic acidemia (MMA), often experience metabolic decompensation episodes characterized by metabolic acidosis and hyperammonemia. The long-term effects of carglumic acid (N-carbamylglutamate) therapy in children with PA and MMA were evaluated using comprehensive assessments including neurodevelopment, growth, and metabolic profiles.Methods: Three pediatric patients diagnosed with organic acidemias (2 PA, 1 MMA) and recurrent metabolic decompensation episodes were administered carglumic acid (50 mg/kg/day). The primary outcomes were total hospitalization days and the annual admission rate due to metabolic decompensation. Secondary outcomes including biochemical tests and adverse events were also evaluated.Results: The patients received carglumic acid for a median duration of 3.2 years (range, 2.8-3.4). Over this period, the median annual hospitalization days decreased from 35 (range, 15–259) to 0 (range, 0–39), and the median annual admission rate from 2 (range, 0.8–4.0) to 0 (range, 0–4). Peak ammonia levels decreased from a median of 411 μmol/L (range, 232–615) to 77 μmol/L (range, 74–80). Plasma levels of isoleucine, valine, and C3-acylcarnitine remained stable. No further deterioration in growth or neurodevelopment was observed. Notably, the MMA patient who received this treatment from 2 months of age achieved age-appropriate developmental milestones after 2.5 years. All three children showed good treatment adherence, and no drug-related adverse events were reported. Additionally, we identified a novel PCCB missense variant, c.520G>C (p.Ala174Pro), in one patient with PA. This variant was detected in trans with a previously reported canonical splice-site variant, c.966+1G>T, and was classified as likely pathogenic according to ACMG/AMP criteria.Conclusion: Early and sustained maintenance therapy with carglumic acid in children with organic acidemias may effectively reduce hyperammonemic decompensation, stabilize metabolic control, and support favorable neurodevelopmental outcomes.
- Open Access
- 10 July 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (7) , e70401
Clinical implementation of a multidisciplinary pipeline for genome sequencing in rare diseases: A prospective, multicenter, observational cohort study
- 10 July 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (7) , e70401
Open AccessClinical implementation of a multidisciplinary pipeline for genome sequencing in rare diseases: A prospective, multicenter, observational cohort study
- Open Access
- 30 June 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (3) , 140-148
Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
Purpose: With improvements in the infant survival rates for high-risk pregnancies, the prevalence of short stature in children born prematurely and small for gestational age (SGA) has also increased. The aim of this study was to compare the effectiveness of recombinant human growth hormone (rhGH) therapy for preterm and full-term SGA children with short stature.Methods: This study included 114 children born SGA (40 preterm and 74 term), who showed no catch-up growth by age 4 years and had undergone rhGH therapy for at least one year. The clinical parameters were reviewed retrospectively.Results: The mean height standard deviation scores (SDSs) for preterm and full-term SGA children at the start of rhGH therapy were -2.97±0.85 and -2.46±0.54, respectively. The mean duration of treatment was 3.3±1.9 years for preterm SGA children and 3.3±1.6 years for full-term SGA children. The height SDS increased to -1.13±0.96 in preterm children and -0.77±0.59 in full-term children by the fourth year of treatment. Full-term SGA children responded better to rhGH therapy than preterm children in the first year of therapy (P=0.03). Serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 levels significantly increased after the start of rhGH therapy (P<0.001).Conclusion: rhGH therapy significantly improved height SDS in both preterm and full-term SGA children, emphasizing the key role of this intervention for managing short stature in children born SGA, regardless of gestational age.
- 30 June 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (3) , 140-148
Open AccessComparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
Purpose: With improvements in the infant survival rates for high-risk pregnancies, the prevalence of short stature in children born prematurely and small for gestational age (SGA) has also increased. The aim of this study was to compare the effectiveness of recombinant human growth hormone (rhGH) therapy for preterm and full-term SGA children with short stature.Methods: This study included 114 children born SGA (40 preterm and 74 term), who showed no catch-up growth by age 4 years and had undergone rhGH therapy for at least one year. The clinical parameters were reviewed retrospectively.Results: The mean height standard deviation scores (SDSs) for preterm and full-term SGA children at the start of rhGH therapy were -2.97±0.85 and -2.46±0.54, respectively. The mean duration of treatment was 3.3±1.9 years for preterm SGA children and 3.3±1.6 years for full-term SGA children. The height SDS increased to -1.13±0.96 in preterm children and -0.77±0.59 in full-term children by the fourth year of treatment. Full-term SGA children responded better to rhGH therapy than preterm children in the first year of therapy (P=0.03). Serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 levels significantly increased after the start of rhGH therapy (P<0.001).Conclusion: rhGH therapy significantly improved height SDS in both preterm and full-term SGA children, emphasizing the key role of this intervention for managing short stature in children born SGA, regardless of gestational age.
- Open Access
- 31 December 2024
- Published by Korean Society of Medical Genetics in Journal of Genetic Medicine
- Vol. 21 (2) , 74-79
Salih myopathy and Feingold syndrome type 1 caused by the TTN and MYCN mutation in an infant with congenital hypotonia
Eunseong Seo, Dohyung Kim, Soojin Hwang, June-Young Koh, Young Seok Ju, Gu-Hwan Kim, and Beom Hee Lee. J Genet Med 2024;21:74-9. https://doi.org/10.5734/JGM.2024.21.2.74
- 31 December 2024
- Published by Korean Society of Medical Genetics in Journal of Genetic Medicine
- Vol. 21 (2) , 74-79
Open AccessSalih myopathy and Feingold syndrome type 1 caused by the TTN and MYCN mutation in an infant with congenital hypotonia
Eunseong Seo, Dohyung Kim, Soojin Hwang, June-Young Koh, Young Seok Ju, Gu-Hwan Kim, and Beom Hee Lee. J Genet Med 2024;21:74-9. https://doi.org/10.5734/JGM.2024.21.2.74
- Open Access
- 30 April 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (2) , 109-118
Long-term endocrine sequelae after hematopoietic stem cell transplantation in children and adolescents
Purpose: As the survival rate from pediatric cancers has increased significantly with advances in treatment modalities, long-term endocrine complications have also risen. This study investigated the frequencies and risks of endocrine sequelae in childhood cancer survivors who received hematopoietic stem cell transplantation (HSCT).Methods: This study included 200 pediatric patients who underwent HSCT. Clinical and endocrinological findings were collected retrospectively. The median follow-up duration after HSCT was 14 years.Results: Endocrine complications occurred in 135 patients (67.5%). Children who underwent HSCT at pubertal age (n=100) were at higher risk of endocrine complications than those who received it at prepubertal age (79% vs. 56%, P=0.001). The most common complication was hypogonadism (40%), followed by dyslipidemia (22%). Short stature and diabetes mellitus were more prevalent in the prepubertal group, whereas hypogonadism and osteoporosis were more common in the pubertal group. Being female, pubertal age at HSCT, and glucocorticoid use were predictors of an increased risk for any complication. Radiation exposure increased the risk of short stature and hypothyroidism. Hypogonadism was significantly associated with being female, pubertal age at HSCT, and high-dose radiation. Pubertal age at HSCT also increased the risks of osteoporosis and dyslipidemia.Conclusion: This study demonstrates that long-term endocrine complications are common after HSCT in children and adolescents. Age at HSCT is a critical factor for endocrine complications after HSCT. These findings suggest that surveillance strategies for endocrine complications in childhood cancer survivors should be specified according to age at HSCT.
- 30 April 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (2) , 109-118
Open AccessLong-term endocrine sequelae after hematopoietic stem cell transplantation in children and adolescents
Purpose: As the survival rate from pediatric cancers has increased significantly with advances in treatment modalities, long-term endocrine complications have also risen. This study investigated the frequencies and risks of endocrine sequelae in childhood cancer survivors who received hematopoietic stem cell transplantation (HSCT).Methods: This study included 200 pediatric patients who underwent HSCT. Clinical and endocrinological findings were collected retrospectively. The median follow-up duration after HSCT was 14 years.Results: Endocrine complications occurred in 135 patients (67.5%). Children who underwent HSCT at pubertal age (n=100) were at higher risk of endocrine complications than those who received it at prepubertal age (79% vs. 56%, P=0.001). The most common complication was hypogonadism (40%), followed by dyslipidemia (22%). Short stature and diabetes mellitus were more prevalent in the prepubertal group, whereas hypogonadism and osteoporosis were more common in the pubertal group. Being female, pubertal age at HSCT, and glucocorticoid use were predictors of an increased risk for any complication. Radiation exposure increased the risk of short stature and hypothyroidism. Hypogonadism was significantly associated with being female, pubertal age at HSCT, and high-dose radiation. Pubertal age at HSCT also increased the risks of osteoporosis and dyslipidemia.Conclusion: This study demonstrates that long-term endocrine complications are common after HSCT in children and adolescents. Age at HSCT is a critical factor for endocrine complications after HSCT. These findings suggest that surveillance strategies for endocrine complications in childhood cancer survivors should be specified according to age at HSCT.
- Open Access
- 5 April 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (4) , e2430
Clinical and genetic characteristics of three patients with congenital insensitivity to pain with anhidrosis: Case reports and a review of the literature
Background: Congenital insensitivity to pain with anhidrosis (CIPA) is an extremely rare autosomal recessive disorder caused by loss‐of‐function mutations of the NTRK1 gene, affecting the autonomic and sensory nervous system. Clinical manifestation is varied and includes recurrent fever, pain insensitivity, anhidrosis, self‐mutilating behavior, and intellectual disability.Methods: Clinical and genetic features were assessed in two males and one female with genetically confirmed CIPA using exome or genome sequencing.Results: CIPA symptoms including recurrent fever, pain insensitivity, and anhidrosis manifested at the age of 1 year (age range: 0.3–8 years). Two patients exhibited self‐mutilation tendencies, intellectual disability, and developmental delay. Four NTRK1 (NM_002529.3) mutations, c.851‐33T>A (p.?), c.2020G>T (p.Asp674Tyr), c.2303C>T (p.Pro768Leu), and c.574‐156_850+1113del (exons 5‐7 del) were identified. Two patients exhibited early onset and severe phenotype, being homozygous for c.851‐33T>A (p.?) mutations and compound heterozygous for c.851‐33T>A (p.?) and c.2020G>T (p.Asp674Tyr) mutation of NTRK1. The third patient with compound heterozygous mutations of c.2303C>T (p.Pro768Leu) and c.574‐156_850+1113del (exons 5‐7 del) displayed a late onset and milder clinical manifestation.Conclusion: All three patients exhibited variable phenotypes and disease severity. This research enriches our understanding of clinical and genetic aspects of CIPA, highlighting variable phenotypes and disease severity.
- 5 April 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (4) , e2430
Open AccessClinical and genetic characteristics of three patients with congenital insensitivity to pain with anhidrosis: Case reports and a review of the literature
Background: Congenital insensitivity to pain with anhidrosis (CIPA) is an extremely rare autosomal recessive disorder caused by loss‐of‐function mutations of the NTRK1 gene, affecting the autonomic and sensory nervous system. Clinical manifestation is varied and includes recurrent fever, pain insensitivity, anhidrosis, self‐mutilating behavior, and intellectual disability.Methods: Clinical and genetic features were assessed in two males and one female with genetically confirmed CIPA using exome or genome sequencing.Results: CIPA symptoms including recurrent fever, pain insensitivity, and anhidrosis manifested at the age of 1 year (age range: 0.3–8 years). Two patients exhibited self‐mutilation tendencies, intellectual disability, and developmental delay. Four NTRK1 (NM_002529.3) mutations, c.851‐33T>A (p.?), c.2020G>T (p.Asp674Tyr), c.2303C>T (p.Pro768Leu), and c.574‐156_850+1113del (exons 5‐7 del) were identified. Two patients exhibited early onset and severe phenotype, being homozygous for c.851‐33T>A (p.?) mutations and compound heterozygous for c.851‐33T>A (p.?) and c.2020G>T (p.Asp674Tyr) mutation of NTRK1. The third patient with compound heterozygous mutations of c.2303C>T (p.Pro768Leu) and c.574‐156_850+1113del (exons 5‐7 del) displayed a late onset and milder clinical manifestation.Conclusion: All three patients exhibited variable phenotypes and disease severity. This research enriches our understanding of clinical and genetic aspects of CIPA, highlighting variable phenotypes and disease severity.
- Open Access
- 1 April 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (7) , 1396-1399
A 10‐year follow‐up of high‐dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease
High-dose ambroxol therapy combined with ERT in patients with neuropathic Gaucher disease.
- 1 April 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (7) , 1396-1399
Open AccessA 10‐year follow‐up of high‐dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease
High-dose ambroxol therapy combined with ERT in patients with neuropathic Gaucher disease.
- Open Access
- 29 February 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (1) , 54-59
Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency through molecular genetic analysis of the CYP21A2 gene
Purpose: Deficiency of 21-hydroxylase (21-OHD) is an autosomal recessively inherited disorder that is characterized by adrenal insufficiency and androgen excess. This study was performed to investigate the clinical utility of prenatal diagnosis of 21-OHD using molecular genetic testing in families at risk.Methods: This study included 27 pregnant women who had previously borne a child with 21-OHD. Fetal tissues were obtained using chorionic villus sampling (CVS) or amniocentesis. After the genomic DNA was isolated, Sanger sequencing of CYP21A2 and multiplex ligation-dependent probe amplification were performed. The clinical and endocrinological findings were reviewed retrospectively.Results: A total of 39 prenatal genetic tests was performed on 27 pregnant women and their fetal tissues. The mean gestational age at the time of testing was 11.7 weeks for CVS and 17.5 weeks for amniocentesis. Eleven fetuses (28.2%) were diagnosed with 21-OHD. Among them, 10 fetuses (90.9%) harbored the same mutation as siblings who were previously diagnosed with 21-OHD. Among these, 4 fetuses (3 males and 1 female) identified as affected were born alive. All 4 patients have been treated with hydrocortisone, 9α-fludrocortisone, and sodium chloride since a mean of 3.7 days of life. The male patients did not show hyponatremia and dehydration, although they harbored pathogenic variants associated with the salt-wasting type of 21-OHD.Conclusion: This study demonstrated the diagnostic efficacy and clinical consequences of diagnosis by prenatal genetic testing in families at risk for 21-OHD. All patients identified as affected were treated with hydrocortisone and 9α-fludrocortisone early after birth, which can prevent a life-threatening adrenal crisis.
- 29 February 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (1) , 54-59
Open AccessPrenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency through molecular genetic analysis of the CYP21A2 gene
Purpose: Deficiency of 21-hydroxylase (21-OHD) is an autosomal recessively inherited disorder that is characterized by adrenal insufficiency and androgen excess. This study was performed to investigate the clinical utility of prenatal diagnosis of 21-OHD using molecular genetic testing in families at risk.Methods: This study included 27 pregnant women who had previously borne a child with 21-OHD. Fetal tissues were obtained using chorionic villus sampling (CVS) or amniocentesis. After the genomic DNA was isolated, Sanger sequencing of CYP21A2 and multiplex ligation-dependent probe amplification were performed. The clinical and endocrinological findings were reviewed retrospectively.Results: A total of 39 prenatal genetic tests was performed on 27 pregnant women and their fetal tissues. The mean gestational age at the time of testing was 11.7 weeks for CVS and 17.5 weeks for amniocentesis. Eleven fetuses (28.2%) were diagnosed with 21-OHD. Among them, 10 fetuses (90.9%) harbored the same mutation as siblings who were previously diagnosed with 21-OHD. Among these, 4 fetuses (3 males and 1 female) identified as affected were born alive. All 4 patients have been treated with hydrocortisone, 9α-fludrocortisone, and sodium chloride since a mean of 3.7 days of life. The male patients did not show hyponatremia and dehydration, although they harbored pathogenic variants associated with the salt-wasting type of 21-OHD.Conclusion: This study demonstrated the diagnostic efficacy and clinical consequences of diagnosis by prenatal genetic testing in families at risk for 21-OHD. All patients identified as affected were treated with hydrocortisone and 9α-fludrocortisone early after birth, which can prevent a life-threatening adrenal crisis.
- Open Access
- 30 September 2023
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 28 (3) , 184-192
Clinical outcomes and genotype-phenotype correlations in patients with complete and partial androgen insensitivity syndromes
Purpose: Androgen insensitivity syndrome (AIS) is a rare X-linked recessive disorder caused by unresponsiveness to androgens because of mutations in the AR gene. Here, we investigated the clinical outcomes and molecular spectrum of AR variants in patients with AIS attending a single academic center.Methods: This study included 19 patients with AIS who were confirmed by molecular analysis of AR. Clinical features and endocrinological findings were retrospectively collected, including presenting features, external genitalia, sex of rearing, timing of gonadectomy, pubertal outcomes, and sex hormone levels. Molecular analysis of AR was performed using Sanger, targeted gene panel, or whole-exome sequencing.Results: Among all 19 patients, 14 (74%) were classified as having complete AIS (CAIS), whereas 5 (26%) had partial AIS (PAIS). All patients with CAIS, and 3 patients with PAIS were reared as female. One patient with CAIS manifested a mixed germ cell tumor at the age of 30 years. Molecular analysis of AR identified 19 sequence variants; 12 (63%) were previously reported, and the remaining 7 (37%) were novel. Missense mutations were the most common type (12 of 19, 63%), followed by small deletions, nonsense mutations, an insertion, and a splice site mutation.Conclusion: Here, we describe the clinical outcomes and molecular characteristics of 19 Korean patients with AIS. Patients with PAIS manifested various degrees of masculinization of the external genitalia. Nonsense and frameshift mutations were frequent in patients with CAIS, whereas patients with PAIS harbored exclusively missense mutations.
- 30 September 2023
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 28 (3) , 184-192
Open AccessClinical outcomes and genotype-phenotype correlations in patients with complete and partial androgen insensitivity syndromes
Purpose: Androgen insensitivity syndrome (AIS) is a rare X-linked recessive disorder caused by unresponsiveness to androgens because of mutations in the AR gene. Here, we investigated the clinical outcomes and molecular spectrum of AR variants in patients with AIS attending a single academic center.Methods: This study included 19 patients with AIS who were confirmed by molecular analysis of AR. Clinical features and endocrinological findings were retrospectively collected, including presenting features, external genitalia, sex of rearing, timing of gonadectomy, pubertal outcomes, and sex hormone levels. Molecular analysis of AR was performed using Sanger, targeted gene panel, or whole-exome sequencing.Results: Among all 19 patients, 14 (74%) were classified as having complete AIS (CAIS), whereas 5 (26%) had partial AIS (PAIS). All patients with CAIS, and 3 patients with PAIS were reared as female. One patient with CAIS manifested a mixed germ cell tumor at the age of 30 years. Molecular analysis of AR identified 19 sequence variants; 12 (63%) were previously reported, and the remaining 7 (37%) were novel. Missense mutations were the most common type (12 of 19, 63%), followed by small deletions, nonsense mutations, an insertion, and a splice site mutation.Conclusion: Here, we describe the clinical outcomes and molecular characteristics of 19 Korean patients with AIS. Patients with PAIS manifested various degrees of masculinization of the external genitalia. Nonsense and frameshift mutations were frequent in patients with CAIS, whereas patients with PAIS harbored exclusively missense mutations.
- Open Access
- 31 March 2022
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 27 (1) , 22-29
Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta
Purpose: Osteogenesis imperfecta (OI) is a rare bone fragility disorder caused by defects in type 1 collagen biosynthesis. This study investigated the genotype-phenotype correlations and the efficacy of pamidronate therapy in patients with OI in a single academic center.Methods: This study included 24 patients with OI. A clinical scoring system was used to evaluate disorder severity. COL1A1 and COL1A2 genes were analyzed in 13 patients using Sanger sequencing. Genotype-phenotype correlations and the efficacy of pamidronate therapy were analyzed through a retrospective medical chart review.Results: Of the 24 patients, 18 (75%) were classified as type I (12 with type Ia and 6 with type Ib), 2 as type III (8.4%), and 4 as type IV (16.7%). Type Ia patients showed relatively higher lumbar bone mineral density (BMD) standard deviation scores (SDS) and lower clinical scores than those with other types. Seven patients with qualitative mutations had lower lumbar BMD-SDS (P=0.015) and higher clinical scores (P=0.008) than 6 patients with quantitative mutations. The annual fracture frequency and lumbar BMD-SDS improved in patients with qualitative mutations after pamidronate treatment.Conclusion: This study demonstrated that OI patients with qualitative mutations in COL1A1/2 had a more severe phenotype than those with quantitative mutations. Patients with qualitative mutations showed a significant reduction in fracture frequency and an increase in lumbar BMD-SDS after pamidronate treatment. Clinical score and genotype might be helpful for predicting phenotype and response to pamidronate therapy in OI patients.
- 31 March 2022
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 27 (1) , 22-29
Open AccessGenotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta
Purpose: Osteogenesis imperfecta (OI) is a rare bone fragility disorder caused by defects in type 1 collagen biosynthesis. This study investigated the genotype-phenotype correlations and the efficacy of pamidronate therapy in patients with OI in a single academic center.Methods: This study included 24 patients with OI. A clinical scoring system was used to evaluate disorder severity. COL1A1 and COL1A2 genes were analyzed in 13 patients using Sanger sequencing. Genotype-phenotype correlations and the efficacy of pamidronate therapy were analyzed through a retrospective medical chart review.Results: Of the 24 patients, 18 (75%) were classified as type I (12 with type Ia and 6 with type Ib), 2 as type III (8.4%), and 4 as type IV (16.7%). Type Ia patients showed relatively higher lumbar bone mineral density (BMD) standard deviation scores (SDS) and lower clinical scores than those with other types. Seven patients with qualitative mutations had lower lumbar BMD-SDS (P=0.015) and higher clinical scores (P=0.008) than 6 patients with quantitative mutations. The annual fracture frequency and lumbar BMD-SDS improved in patients with qualitative mutations after pamidronate treatment.Conclusion: This study demonstrated that OI patients with qualitative mutations in COL1A1/2 had a more severe phenotype than those with quantitative mutations. Patients with qualitative mutations showed a significant reduction in fracture frequency and an increase in lumbar BMD-SDS after pamidronate treatment. Clinical score and genotype might be helpful for predicting phenotype and response to pamidronate therapy in OI patients.